Coss-Phelps Lab: "Jabez Biosciences Presents First-in-Human Pharmacokinetic and Pharmacodynamic Data for JBZ-001 at AACR Annual Meeting 2026"

Jabez Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapies targeting cancer metabolism, today announced the presentation of first-in-human pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 clinical trial of JBZ-001 (HOSU-53) at the American Association for Cancer Research (AACR) Annual Meeting 2026. The poster, titled "Clinical Pharmacokinetic and Pharmacodynamic of JBZ-001 (HOSU-53): Comparison of First-in-Human Data with Translational Preclinical Predictions," was presented by investigators from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the START Center for Cancer Research.

Poster Presentation Details